and development of
new antibiotics and
The Netherlands Antibiotic Development Platform
The Netherlands Antibiotic Development Platform (NADP) facilitates the collaboration between public and private organisations, to enhance the development of new antibiotics and alternative therapies for infectious diseases in humans and animals.
NADP will identify relevant research groups, institutes and companies involved in chemical, biological, and/or biomedical antibiotic research to forge collaborations through targeted connections and will organise regular meetings with interested parties.
Stay informed on NADP and subscribe to our Update.
An important objective of NADP is to increase R&D productivity related to new antibiotics and alternatives. To promote the accelerated development of promising 'leads', NADP has developed a financing instrument specifically for this purpose: the NADP Vouchers.
These vouchers can be used in various phases of drug development to gain advice and intensive supervision of research projects from independent consultants or CROs that have specific knowledge and expertise pertinent to the pharmaceutical development process and clinical applications.
A record number of countries are now monitoring and reporting on antibiotic resistance – marking a major step forward in the global fight against drug resistance. But the data they provide reveals that a worrying number of bacterial infections are increasingly resistant to the medicines at hand to treat them.
Companies, institutions and individuals are invited to submit data on their products that are in the preclinical pipeline that fulfil the below inclusion criteria. Data submitted should be non-confidential and will be made available publicly on the WHO Global Health R&D Observatory.
Identifying potential antibiotic leads is painfully slow, but these researchers identified 5 in only 6 years
ENABLE surpassed their goal of identifying 3 leads for new antibiotics. With several more compounds in the pipeline, the project has been extended.